Related Experiment Video
Updated: May 1, 2026
Neutrophil Isolation and Analysis to Determine their Role in Lymphoma Cell Sensitivity to Therapeutic Agents
Published on: March 25, 2016
Outcomes of pirtobrutinib for relapsed/refractory mantle cell lymphoma in compassionate use program in Europe
Enver Aydilek1, Gerald Wulf1, Friedrich Schwarz1,2
1Department for Hematology and Medical Oncology, University Medical Center Göttingen, Göttingen, Germany.
Background:
Mantle cell lymphoma (MCL) is a type of B-cell lymphoma that is currently incurable. Pirtobrutinib shows promising response rates in heavily pretreated MCL patients according to the approval study, but the real-world data are scarce.
Methods:
In this study, we retrospectively analyzed the efficacy and safety profile of pirtobrutinib in 10 relapsed/refractory MCL patients from compassionate use program (CUP).
Results:
On average, the patients underwent three lines of systemic therapy prior to pirtobrutinib and were predominantly BTKi exposed (9/10). The best overall response rate (BORR) was 67%. In a median follow-up of 8.6 months, the mean duration of response (DOR), progression-free survival (PFS), and overall survival (OS) were not reached. No new safety signals were documented.
Conclusions:
In summary, pirtobrutinib represented a safe and effective treatment option in a small real-world population.
More Related Videos
Related Concept Videos
02:56Treatment Resistant Cancers
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF